Authors: Malhotra V, Patel SG, Feinaj A, Amin D, Ash H, Boozo MB, Breslow Z, Trube J, Farooq MZ, Sabina M.
DOI: 10.3389/fonc.2025.1690984
Abstract Summary
Meta-analysis of 2,126 cancer patients shows that reducing apixaban from 5mg to 2.5mg twice daily after six months of anticoagulation significantly lowers bleeding risk without increasing recurrent blood clots. This dose de-escalation strategy offers a safer approach for extended treatment of cancer-associated venous thromboembolism, addressing a critical need in patients requiring prolonged anticoagulation.
Why Brain? ðŸ§
Lower-dose apixaban after 6 months reduces bleeding risk in cancer patients with blood clots without increasing clot recurrence, offering a safer long-term anticoagulation strategy.
License: CC BY.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
